JHU startup PathoVax raises $2.75M, grows team - Technical.ly Baltimore

Business

Oct. 18, 2018 6:01 pm

JHU startup PathoVax raises $2.75M, grows team

The company is working toward clinical trials of its HPV vaccine.

PathoVax team members (L to R): Ken Matsui, Pola Olczak, Nattha Ingavat (Patt), Ameya Gokhale, cofounder Joshua Wang, Huimin Tan.

(Courtesy photo)

PathoVax, a Johns Hopkins–born startup developing a vaccine for human papillomavirus virus (HPV), raised $2.75 million in new funding, cofounder Joshua Wang said.

The equity funding round was led by United Heath Investments. The life science investment group is led by Dr. Alan Zhu, who is also director of the Baltimore-based Chinese Association for Medical Professionals, which counts 800 physicians as members and seeks to strengthen ties between medical communities in the U.S. and China. Private investors also participated.

The startup is developing RGVax, a vaccine that is designed to protect against all cancer-causing forms of HPV. Vaccines against the are already available, but only protect against some strains of the disease.

Wang and cofounder Weijie Poh began working on the technology while they were PhD students working in the lab of inventor Richard Roden at the Johns Hopkins University School of Medicine.

The cofounders are alums of 43North, a Buffalo accelerator. Late last year, the company also received U.S. Small Business Innovation Research grant funding totaling about $2.3 million, Wang said.

“Since then we’ve grown from a 2-person team to six employees and have been focused on pushing the vaccine toward first in human trials,” Wang said.

The startup also recently moved into Johns Hopkins’ FastForward 1812 innovation hub. Along with targeting clinical trials in the first half of 2020, the company is also identifying other applications of the technology.

The equity funding, Wang said, is aimed at “building the business side of the company.” The company is looking to bring on team members who are experienced in areas such as management and manufacturing.

Companies: PathoVax
-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

The acquisition deal for Columbia-based Osiris Therapeutics is now complete

VitusVet moves to Baltimore from Columbia, plans hiring

MICA’s UP/Start Venture Competition meant progress and funding for these 8 startups

SPONSORED

Baltimore

How SmartLogic accelerated these startups’ product growth trajectories

Baltimore, MD 21201

14 West

Junior Database Administrator

Apply Now
Philadelphia, PA

Orthly

Full-Stack Javascript Engineer

Apply Now
Baltimore, MD 21201

14 West

Chief of Staff

Apply Now

Baltimore’s Paragon Bioservices to be acquired by drug manufacturer Catalent for $1.2B

Paragon Bioservices expands, plans hires with new manufacturing facility

Power Moves: Frank Bonsal III is leaving TU incubator, returning to venture capital

SPONSORED

Baltimore

This fast-growing SaaS company aims to be a force for change in the energy industry

Baltimore, MD

SmartLogic

Product Designer

Apply Now
Baltimore

Technically Media

Technical.ly Baltimore Contributing Reporter (Contract or Freelance)

Apply Now
Baltimore, MD

SmartLogic

Developer

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!